Veradermics VDPHL01 hits all Phase 3 '304' endpoints; TAHC up 28.6-36.4 hairs/cm² vs 6.6 placebo

Veradermics, Inc

Study '304' randomized 536 males with mild-to-moderate pattern hair loss to VDPHL01 8.5mg once-daily, twice-daily or placebo; all primary and secondary endpoints met (p<0.0001).
Non-vellus target area hair count rose 28.6 hairs/cm² (QD) and 36.4 hairs/cm² (BID) at Month 6 vs 6.6 for placebo; significant separation from placebo seen as early as Month 2.
55.7% (QD) and 68.7% (BID) reported 'improved' or 'much improved' hair coverage on AAIRS vs 15.0% placebo; investigator IGA rated 78.4% and 82.7% improved.
No treatment-related SAEs and no cardiac AESIs; hypertrichosis was the only TEAE >5% with an imbalance (2.2% QD, 9.0% BID); peripheral edema 2.8%/4.5% vs 0.6% placebo.
Part B 12-month data from Study '302' expected later in 2026; female pattern hair loss Study '306' topline anticipated in H1 2027.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.